CN100356919C - 羟基喜树碱脂质体及其制备方法 - Google Patents
羟基喜树碱脂质体及其制备方法 Download PDFInfo
- Publication number
- CN100356919C CN100356919C CNB2004100247956A CN200410024795A CN100356919C CN 100356919 C CN100356919 C CN 100356919C CN B2004100247956 A CNB2004100247956 A CN B2004100247956A CN 200410024795 A CN200410024795 A CN 200410024795A CN 100356919 C CN100356919 C CN 100356919C
- Authority
- CN
- China
- Prior art keywords
- liposome
- hydroxy camptothecin
- hydroxycamptothecin
- phospholipid
- thin film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 title claims abstract description 56
- 239000002502 liposome Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 9
- 239000011248 coating agent Substances 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims abstract description 9
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 230000008020 evaporation Effects 0.000 claims abstract 2
- 238000001704 evaporation Methods 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000010408 film Substances 0.000 claims description 13
- 239000000232 Lipid Bilayer Substances 0.000 claims description 11
- 239000010409 thin film Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229940042880 natural phospholipid Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 9
- 230000036571 hydration Effects 0.000 abstract description 5
- 238000006703 hydration reaction Methods 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 238000007142 ring opening reaction Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 150000002596 lactones Chemical group 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 239000002344 surface layer Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- -1 Polyethylene Polymers 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
1 | 2 | 3 | 4 | 5 | 6 | |
浓度c(μg/ml) | 0.0412 | 0.412 | 0.824 | 2.06 | 4.12 | 20.6 |
峰面积A | 3.7 | 33.2 | 57.7 | 152.5 | 301.7 | 1515.4 |
3.6 | 32.9 | 57.1 | 148.9 | 299.6 | 1514.9 | |
峰面积平均值A平 | 3.6 | 33.0 | 57.4 | 150.7 | 300.6 | 1515.2 |
作用靶点(2小时) | HCPT-LCL | 游离药物 |
胃癌细胞(SGC-7901)正常细胞(大鼠胚胎成纤维细胞) | 25.6>100 | 75.569 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100247956A CN100356919C (zh) | 2004-05-31 | 2004-05-31 | 羟基喜树碱脂质体及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100247956A CN100356919C (zh) | 2004-05-31 | 2004-05-31 | 羟基喜树碱脂质体及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1582932A CN1582932A (zh) | 2005-02-23 |
CN100356919C true CN100356919C (zh) | 2007-12-26 |
Family
ID=34600985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100247956A Expired - Lifetime CN100356919C (zh) | 2004-05-31 | 2004-05-31 | 羟基喜树碱脂质体及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100356919C (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1843368B (zh) * | 2005-04-06 | 2010-04-28 | 清华大学 | 一种灯盏花素长循环纳米脂质体及其制备方法 |
CN1698611B (zh) * | 2005-06-07 | 2010-12-08 | 华东理工大学 | 纳米马钱子碱脂质体及其制备方法 |
CN1875944B (zh) * | 2006-06-29 | 2011-01-05 | 中国科学院上海药物研究所 | 一种聚乙二醇修饰的羟基喜树碱隐形脂质纳米球及其制备方法 |
ES2618457T3 (es) | 2007-03-30 | 2017-06-21 | Hirofumi Takeuchi | Liposoma transpulmonar para controlar la llegada del fármaco |
CN101732349B (zh) * | 2008-11-14 | 2012-05-23 | 上海医药工业研究院 | 一种蟾酥纳米长循环脂质体及其制备方法 |
AR076634A1 (es) * | 2008-11-21 | 2011-06-29 | Medgenesis Therapeutix Inc | Composiciones y metodo para tratar desordenes del sistema nervioso central |
WO2010111807A1 (zh) * | 2009-04-03 | 2010-10-07 | 武汉大安制药有限公司 | 一种多糖脂质体、其制备方法及用途 |
CN103690556B (zh) * | 2014-01-06 | 2016-04-20 | 济南大学 | 一种羟基喜树碱长循环脂质体 |
CN105777770B (zh) * | 2014-12-26 | 2018-05-25 | 中国人民解放军第二军医大学 | 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体 |
CN116327701A (zh) * | 2023-02-27 | 2023-06-27 | 北京大学深圳医院(北京大学深圳临床医学院) | 用于治疗肝纤维化的复合纳米脂质体及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008986A1 (en) * | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
-
2004
- 2004-05-31 CN CNB2004100247956A patent/CN100356919C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008986A1 (en) * | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
Non-Patent Citations (2)
Title |
---|
脂质体的研究概况 张冬青,程怡.中药新药与临床药理,第13卷第2期 2002 * |
表面活性剂在新剂型中的应用 施洁明,何仲贵.中国药房,第14卷第3期 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1582932A (zh) | 2005-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Roles of ligand and TPGS of micelles in regulating internalization, penetration and accumulation against sensitive or resistant tumor and therapy for multidrug resistant tumors | |
CN100356919C (zh) | 羟基喜树碱脂质体及其制备方法 | |
CN104523597B (zh) | 一种鬼臼毒素类药物的靶向给药制剂 | |
CN106474064B (zh) | 一种蒿甲醚纳米脂质体及其制备方法与应用 | |
CN104000783B (zh) | 头孢喹肟脂质体 | |
CN105669964A (zh) | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 | |
CN101953792B (zh) | 伊立替康纳米长循环脂质体及其制备方法 | |
CN101612124B (zh) | 一种类脂质体及其制剂的制备方法 | |
Lin et al. | A comparative investigation between paclitaxel nanoparticle-and nanocrystal-loaded thermosensitive PECT hydrogels for peri-tumoural administration | |
JP6884783B2 (ja) | リポソームの製造方法 | |
CN101933904A (zh) | 一种长春瑞滨长循环脂质体制剂及其制备方法 | |
CN101780042A (zh) | 一种紫杉醇纳米靶向缓释长循环脂质体及其制备方法 | |
CN102379850B (zh) | 一种穿越人体粘液屏障的靶向给药脂质体 | |
CN101732349B (zh) | 一种蟾酥纳米长循环脂质体及其制备方法 | |
CN109260177A (zh) | 一种盐酸小檗碱复合物纳米粒的制备方法及其应用 | |
CN103585106B (zh) | 一种pH敏感性修饰脂质体及其制备方法 | |
CN109481404A (zh) | 一种pH敏感咪唑脂质体的制备方法 | |
CN100364525C (zh) | 含壳聚糖衍生物的多西他塞脂质体、冻干制剂及制备方法 | |
CN103040910A (zh) | 一种鹿瓜多肽脂质体注射剂 | |
CN100525758C (zh) | 藤黄酸脂质体及其冻干粉针剂与制备方法 | |
CN101264057A (zh) | pH敏感长循环脂质体组合物及其制备方法 | |
CN101455845A (zh) | 奥曲肽为靶向配基的聚乙二醇修饰磷脂衍生物及其制法 | |
Akram et al. | Liposomes: a promising delivery system for active ingredients in food and nutrition | |
CN110251466A (zh) | 一种大麻二酚脂质体及制备工艺 | |
CN101884616A (zh) | 一种多西紫杉醇长循环脂质体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: FENG JIANFANG Free format text: FORMER OWNER: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY Effective date: 20130314 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200040 HUANGPU, SHANGHAI TO: 201203 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130314 Address after: 201203 Shanghai Cailun Road No. 1200 Patentee after: Feng Jianfang Address before: 200040 Beijing West Road, Shanghai, No. 1320 Patentee before: Shanghai Institute of pharmaceutical industry |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170602 Address after: 410205, 1201-1203, 1211, building 12, building, extension, agriculture building, 459 Dongfanghong Road, Changsha high tech Development Zone, Changsha, Hunan Patentee after: Hunan Yineng Biological Pharmaceutical Co.,Ltd. Address before: 201203 Shanghai Cailun Road No. 1200 Patentee before: Feng Jianfang |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20071226 |
|
CX01 | Expiry of patent term |